Lizzie Fletcher is having a busy week on the Hill. On the fourth anniversary of Dobbs, the Houston Democrat joined three colleagues to introduce legislation closing the abortion-training gap for OB/GYN residents stuck in ban states. Good optics. Meanwhile, her financial disclosures tell a quieter story: on a single Tuesday in April, she sold 11 different stocks. Every single one. The mean 30-day alpha across those trades came in at negative 3.9 percent. Four out of 11 positions beat the market. The other seven did not. And three of the trades that outperformed sit squarely inside her committee's jurisdiction.
The Bill in the Headlines
The legislation Fletcher announced alongside Reps. Kelly Morrison, Kim Schrier, and Ami Bera would let OB/GYN residents in abortion-ban states complete their training at federally funded sites elsewhere. Quiver Quantitative flagged the release alongside Fletcher's own congressional site. The bill is squarely in her wheelhouse: Fletcher sits on the House Committee on Energy and Commerce, including the Health and Oversight subcommittees, which means reproductive health policy is genuinely her lane, not just a press opportunity.
Whether the bill moves anywhere in a Republican-controlled House is a separate question. The answer is almost certainly no. But it generates a news cycle, and on the Dobbs anniversary, that's the point.
April 8: One Day, Eleven Sales
Set the bill aside for a moment and look at the brokerage activity.
On April 8, 2026, Fletcher's disclosed filings show she sold positions in Alphabet, Ameriprise Financial, Apple, Eli Lilly, JPMorgan Chase, KLA Corporation, McKesson, Microsoft, Nvidia, Quanta Services, and Eaton. Eleven tickers, one date. Each position fell in the $1,000 to $15,000 range per the disclosure. That's the full snapshot she's required to report under the STOCK Act, and it's a lot of selling to compress into a single trading day.
What actually happened in the market on April 8? The S&P 500 was in the middle of a brutal stretch. Tariff-driven volatility had hammered equities through late March and early April, and April 8 landed inside that window. Selling broad-market positions into a downdraft is not unusual. The question is always what happened next.
The Scorecard: 4 for 11
Here's what the 30-day alpha record looks like on those 11 sales, per Blind Trust's scoring.
Four trades outperformed the S&P 500 in the 30 days after the sale. Seven did not. The mean alpha across the full sample: negative 3.9 percent. That means, on average, the positions she sold went on to do better than selling them suggested. The portfolio bled relative to the index.
The worst performer in the group was McKesson, down 23.2 percent on a 30-day alpha basis after the sale. JPMorgan Chase came in at negative 6.3 percent. Eli Lilly clocked negative 16.0 percent. All three of those kept falling after she sold, which in pure numerical terms means the sales looked smart in hindsight for those specific names. A negative alpha on a sale means the stock underperformed the market after she exited. She got out before it got worse.
The trades that posted positive alpha: Nvidia at plus 5.6 percent, Microsoft at plus 2.0 percent, Alphabet at plus 1.7 percent. Those three bounced after she sold. From a pure alpha standpoint, those were the misfires. She sold, the stocks recovered relative to the index, and the exit looked poorly timed.
The full record is 4 wins and 7 losses on 11 scored trades. Not a pattern worth calling a strategy. It's a portfolio getting sold into volatility with uneven results, which is a description that fits a lot of April 2026 activity from a lot of people who had no view on anything.
Where the Committee Angle Lives
Most of these trades carry no committee-level angle. Fletcher doesn't sit on Financial Services, so the JPMorgan sale is just a sale. She's not on any committee with jurisdiction over industrial conglomerates, so Eaton and Quanta Services are just trades.
Five of the 11, though, land in territory where her committee assignments create a different frame.
Fletcher sits on the Energy and Commerce Committee, including the Health subcommittee. That committee has direct oversight jurisdiction over pharmaceutical companies and technology firms operating in the health and commerce space. The five overlap trades:
- Nvidia (NVDA): sold April 8, plus 5.6% alpha over 30 days. Technology overlap.
- Microsoft (MSFT): sold April 8, plus 2.0% alpha over 30 days. Technology overlap.
- Alphabet (GOOGL): sold April 8, plus 1.7% alpha over 30 days. Technology overlap.
- Apple (AAPL): sold April 8, minus 0.9% alpha over 30 days. Technology overlap.
- Eli Lilly (LLY): sold April 8, minus 16.0% alpha over 30 days. Pharmaceuticals overlap.
Three of the four trades that posted positive alpha were in sectors under her committee's oversight. The tech names bounced. The pharma name, Eli Lilly, kept falling. Three out of five committee-overlap trades outperformed after she exited. The interpretation is yours.
What the system requires: disclosure within 45 days of the transaction. What it doesn't require: recusal, divestiture, or any explanation at all for why a member of the Health and Oversight subcommittee held and sold large-cap technology and pharmaceutical positions while her committee conducted its business. Members are required to report. They are not required to do anything else.
The Votes Running Alongside
Fletcher's recent floor votes run in a different direction from her portfolio's sector exposure. In May, she voted yes on the American Access to Banking Act and the Community Bank Deposit Access Act, two banking-adjacent bills with high market relevance scores that cleared the floor on May 20. She also voted yes on the Keeping Deposits Local Act the same day. None of those banking votes overlap with her committee assignments, so there's no COI angle there. She's just a member voting on the floor like every other member.
She voted no on the FISA reauthorization in June and no on the Veterans 2nd Amendment Protection Act in May. Her yes on the 21st Century ROAD to Housing Act in June rounds out a recent voting record that looks like a Democrat in a swing-adjacent Houston seat threading a standard ideological needle.
Nothing in the vote record maps cleanly onto the April 8 trading date. The two events are weeks apart. The vote-trade overlap list in the data is empty.
The Bigger Picture
Today, Fletcher is getting covered for a bill about abortion training. That's the version of her the press release machine produces. The financial disclosures produce a different version: a member who unloaded 11 positions in one day in April, posted a negative 3.9 percent mean alpha across the full batch, and happened to time exits from three tech-sector stocks inside her committee's jurisdiction in a way that beat the market by 1.7 to 5.6 percentage points over the following month.
The Eli Lilly sale is the one that cuts the other way. She sold a pharmaceutical stock, also inside her committee's jurisdiction, and Lilly dropped 16 percent relative to the S&P 500 in the 30 days after. On pure numbers, that was the best-timed sale in the bunch. It was also the one in the sector most directly in the crosshairs of her Health subcommittee work.
Seven of the 11 trades posted negative alpha. It's an uneven batch of sales on a volatile day in April, with a few results that land on the interesting side of the ledger and a majority that don't.
The receipts are public. Make of them what you make of them.